Predictive Oncology
POAI
Market cap $8.57M

0.9600 USD

-0.0300

3.03%

At close Jun 13, 4:00 PM EDT

1 day

-3.03%

5 days

5.41%

1 month

-12.73%

3 months

-11.93%

6 months

23.09%

Year to date

4.35%

1 year

-23.81%

5 years

-97.26%

10 years

-99.90%

About: Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

Employees: 24

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

42% more capital invested

Capital invested by funds: $197K [Q4 2024] → $281K (+$83.3K) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

1.05% less ownership

Funds ownership: 3.61% [Q4 2024] → 2.56% (-1.05%) [Q1 2025]

11% less funds holding

Funds holding: 18 [Q4 2024] → 16 (-2) [Q1 2025]

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for POAI.

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about POAI published over the past 30 days

Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp

Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapies Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapies

Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp

Court Denies Renovaro Motion for an Expedited Trial in July

PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc.

Court Denies Renovaro Motion for an Expedited Trial in July

AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition

Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples

AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition

Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health"

Latest developments expand Predictive's AI-driven drug discovery platform to include biomarker discovery and drug repurposing

Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health"

Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended March 31, 2025, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $110,310 for the quarter.

Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update

PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended December 31, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $10.8 million on total revenue of $1.6 million for the year ended December 31, 2024.

Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update

Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary

Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan

Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary

Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries

Deal positions STREAMWAY ® Systems with an established market leader to drive accelerating growth

Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries

Predictive Oncology Closes Registered Direct Offering

PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its previously announced registered direct offering for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share priced at-the-market under Nasdaq rules.

Predictive Oncology Closes Registered Direct Offering

Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing

Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types

Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing

See News Rankings

Charts implemented using Lightweight Charts™